Connect Biopharma Holdings (CNTB) Cash from Financing Activities (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Cash from Financing Activities of $17.6 million for Q1 2026, up 2364.62% sequentially from $715000.0 in Q4 2025, and up 881000.0% YoY from N/an in Q1 2025.
Connect Biopharma Holdings (CNTB) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Cash from Financing Activities for 3 years, with the latest figure at $17.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 881000.0% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 8071.62% YoY) and the FY2025 annual result came in at $1.1 million, up 381.5% from the prior year.
- Cash from Financing Activities rose to $17.6 million in Q1 2026 per CNTB's latest filing, from $715000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $17.6 million in Q1 2026 and troughed at $2000.0 in Q1 2025.
- A 3-year average of $2.7 million and a median of $161000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities soared 33.06% in 2025, then soared 881000.0% in 2026.
- Over 3 years, Cash from Financing Activities stood at $106000.0 in 2024, then surged by 574.53% to $715000.0 in 2025, then soared by 2364.62% to $17.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $17.6 million, $715000.0, and $215000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Mn |
| Jun 30, 2026 | 1.33 Mn |
| Mar 31, 2026 | 17.62 Mn |
| Mar 31, 2026 | 17.62 Mn |
| Dec 31, 2025 | 715,000.00 |
| Dec 31, 2025 | 715,000.00 |
| Sep 30, 2025 | 215,000.00 |
| Sep 30, 2025 | 215,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Dec 31, 2024 | 106,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 121,000.00 |